BR0108043A - Substância para uso em complementação de dieta ou para preparação de um medicamento para o tratamento de diabetes melito não-dependente de insulina, hipertensão e/ou sìndrome metabólica - Google Patents

Substância para uso em complementação de dieta ou para preparação de um medicamento para o tratamento de diabetes melito não-dependente de insulina, hipertensão e/ou sìndrome metabólica

Info

Publication number
BR0108043A
BR0108043A BR0108043-1A BR0108043A BR0108043A BR 0108043 A BR0108043 A BR 0108043A BR 0108043 A BR0108043 A BR 0108043A BR 0108043 A BR0108043 A BR 0108043A
Authority
BR
Brazil
Prior art keywords
treatment
hypertension
chemical structures
substance
dietary supplement
Prior art date
Application number
BR0108043-1A
Other languages
English (en)
Inventor
Kjeld Hermansen
Soren Gregersen
Per Bendix Jeppesen
Original Assignee
Stevia Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stevia Aps filed Critical Stevia Aps
Publication of BR0108043A publication Critical patent/BR0108043A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/62—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings
    • C07C13/66—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings the condensed ring system contains only four rings
    • C07C13/68—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings the condensed ring system contains only four rings with a bridged ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/35—Unsaturated compounds having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/86—Ring systems containing bridged rings containing four rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"SUBSTâNCIA PARA USO EM COMPLEMENTAçãO DE DIETA OU PARA PREPARAçãO DE UM MEDICAMENTO PARA O TRATAMENTO DE DIABETES MELITO NãO-DEPENDENTE DE INSULINA, HIPERTENSãO E/OU SìNDROME METABóLICA". Substância incluindo as estruturas químicas de biciclo[3.2.1] octano ou as estruturas químicas de caureno para uso em uma complementação de dieta ou como um constituinte em um medicamento para o tratamento de diabetes melito não-dependente de insulina, hipertensão e/ou síndrome metabólica. As estruturas químicas únicas de biciclo[3.2.1]octano sozinhas ou em uma estrutura de cureno fornecem as substâncias, tais como, esteviol, isoesteviol e esteviosídeo com a capacidade de melhorar ou potencializar a secreção de insulina em uma maneira dependente de glicose no plasma. As substâncias incluindo estas estruturas químicas únicas também possuem a capacidade de reduzir a concentração de glucagon no sangue e/ou abaixar a pressão sang³ínea, desta forma provendo um sistema de tratamento auto-regulador para diabetes melito não-dependente de insulina e/ou hipertensão. Em uma combinação de medicamento que também compreende uma proteína de soja e/ou fibra de soja e/ou pelo menos uma isoflavona, estas substâncias atuam sinergisticamente e tais medicamentos em combinação são muito utilizáveis ambas profilática ou diretamente no tratamento, por exemplo, da síndrome metabólica e da obesidade e isto devido ao efeito auto-regulador de aplicabilidade difundida com uma complementação da dieta.
BR0108043-1A 2000-02-01 2001-02-01 Substância para uso em complementação de dieta ou para preparação de um medicamento para o tratamento de diabetes melito não-dependente de insulina, hipertensão e/ou sìndrome metabólica BR0108043A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200000163 2000-02-01
PCT/DK2001/000075 WO2001056959A1 (en) 2000-02-01 2001-02-01 A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

Publications (1)

Publication Number Publication Date
BR0108043A true BR0108043A (pt) 2003-04-01

Family

ID=8159060

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108043-1A BR0108043A (pt) 2000-02-01 2001-02-01 Substância para uso em complementação de dieta ou para preparação de um medicamento para o tratamento de diabetes melito não-dependente de insulina, hipertensão e/ou sìndrome metabólica

Country Status (8)

Country Link
US (5) US20030060428A1 (pt)
EP (2) EP1255718A1 (pt)
JP (2) JP2003521528A (pt)
CN (1) CN100475757C (pt)
AU (1) AU784422B2 (pt)
BR (1) BR0108043A (pt)
CA (2) CA2762121A1 (pt)
WO (1) WO2001056959A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056959A1 (en) 2000-02-01 2001-08-09 Stevia Aps A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
EP1648483B1 (en) * 2003-06-30 2008-06-04 Nestec S.A. Composition for treating and/or preventing insulin resistance
AT502270B1 (de) * 2005-02-21 2007-07-15 Emakos Naturnahe Nahrungsmitte Verfahren zum modifizieren von steviosid durch austauschreaktionen
US8956677B2 (en) * 2005-11-23 2015-02-17 The Coca-Cola Company High-potency sweetener composition with glucosamine and compositions sweetened therewith
US20070134391A1 (en) * 2005-11-23 2007-06-14 The Coca-Cola Company High-Potency Sweetener Composition for Treatment and/or Prevention of Autoimmune Disorders and Compositions Sweetened Therewith
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8367138B2 (en) * 2005-11-23 2013-02-05 The Coca-Cola Company Dairy composition with high-potency sweetener
US8956678B2 (en) * 2005-11-23 2015-02-17 The Coca-Cola Company High-potency sweetener composition with preservative and compositions sweetened therewith
US8940350B2 (en) * 2005-11-23 2015-01-27 The Coca-Cola Company Cereal compositions comprising high-potency sweeteners
US8435588B2 (en) * 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
US8940351B2 (en) * 2005-11-23 2015-01-27 The Coca-Cola Company Baked goods comprising high-potency sweetener
EP1971228A1 (en) * 2005-11-23 2008-09-24 The Coca-Cola Company Natural high-potency sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses
US20070116831A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company Dental Composition with High-Potency Sweetener
US20070116822A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-potency sweetener composition with saponin and compositions sweetened therewith
US20070116836A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition for Treatment and/or Prevention of Osteoporosis and Compositions Sweetened Therewith
US8993027B2 (en) * 2005-11-23 2015-03-31 The Coca-Cola Company Natural high-potency tabletop sweetener compositions with improved temporal and/or flavor profile, methods for their formulation, and uses
US8524303B2 (en) * 2005-11-23 2013-09-03 The Coca-Cola Company High-potency sweetener composition with phytosterol and compositions sweetened therewith
US8524304B2 (en) * 2005-11-23 2013-09-03 The Coca-Cola Company High-potency sweetener composition with probiotics/prebiotics and compositions sweetened therewith
US9144251B2 (en) * 2005-11-23 2015-09-29 The Coca-Cola Company High-potency sweetener composition with mineral and compositions sweetened therewith
CA2629556A1 (en) * 2005-11-23 2007-07-19 The Coca Cola Company Synthetic sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses
US20100093861A1 (en) * 2006-09-15 2010-04-15 Stevia Aps Treatment of insulin resistance or diseases associated with insulin resistance
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US20080107787A1 (en) * 2006-11-02 2008-05-08 The Coca-Cola Company Anti-Diabetic Composition with High-Potency Sweetener
US9101161B2 (en) * 2006-11-02 2015-08-11 The Coca-Cola Company High-potency sweetener composition with phytoestrogen and compositions sweetened therewith
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
MY155722A (en) * 2007-12-03 2015-11-30 Dsm Ip Assets Bv Novel nutraceutical compositions containing stevia extract or stevia extract constituents and uses thereof
WO2009071099A1 (en) * 2007-12-05 2009-06-11 Aarhus Universitet Elevation of the plasma hdl-cholesterol level
EP2456450A1 (en) * 2009-07-21 2012-05-30 DSM IP Assets B.V. Stevia extract or steviol for hair care
WO2011033524A2 (en) 2009-08-04 2011-03-24 Laila Nutraceuticals Agents from ficus hispida for the amelioration of metabolic syndrome and related diseases
US20110189360A1 (en) * 2010-02-04 2011-08-04 Pepsico, Inc. Method to Increase Solubility Limit of Rebaudioside D in an Aqueous Solution
KR101759767B1 (ko) * 2011-03-18 2017-07-19 페브리스 바이오-텍 리미티드 다중-약물 내성 말라리아를 치료하기 위한 조성물 및 방법
WO2014173418A1 (en) 2013-04-23 2014-10-30 Aarhus Universitet Compositions for use in restoring muscle glycogen and/or muscle mass
RU2525593C1 (ru) * 2013-05-24 2014-08-20 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения Российской Федерации Способ комплексного лечения артериальной гипертонии при метаболических нарушениях
TWI516474B (zh) 2013-05-27 2016-01-11 中央研究院 良薑化合物及其類似物之合成
SG11201510062VA (en) 2013-06-10 2016-01-28 Suntory Holdings Ltd Plant extract containing diketopiperazine and method for producing same
WO2017018404A1 (ja) * 2015-07-27 2017-02-02 サントリーホールディングス株式会社 環状ジペプチド及び甘味料を含有する組成物
CN112716929B (zh) * 2015-09-10 2023-03-31 东莞市凯法生物医药有限公司 贝壳杉烷类化合物在治疗心室增大及重构的药物应用
AU2017345605B2 (en) 2016-10-20 2022-04-14 The Coca-Cola Company Diterpene glycosides isolated from Stevia, compositions and methods
CN108159034B (zh) * 2018-02-12 2019-10-11 东南大学 异甜菊醇在制备治疗非酒精性脂肪性肝病药物中的应用
JPWO2020218382A1 (pt) * 2019-04-26 2020-10-29
CN111357979A (zh) * 2019-12-26 2020-07-03 浙江欧谱生物科技有限公司 抑制高脂引起的肥胖及骨丢失的保健食品组合物及其应用
CN111233702A (zh) * 2020-01-20 2020-06-05 中国科学院昆明植物研究所 先花铃子香素a衍生物与其药物组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626441B1 (en) * 1983-10-06 1991-02-19 Dietetic frozen desserts containing aspartame
JPS63146813A (ja) * 1986-12-11 1988-06-18 Toa Nenryo Kogyo Kk ジテルペン系化合物を含んで成る制癌剤
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
EP0565785A1 (en) 1992-04-07 1993-10-20 Harry H. Leveen Use of glucose transport inhibitors for the treatment for acne
FR2695317B1 (fr) * 1992-09-07 1995-03-10 Monal Lab Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
JPH0813251B2 (ja) * 1993-07-14 1996-02-14 長岡香料株式会社 鉄及び又はマグネシウム及び又はカルシウムを含む呈味改善液
CN1094580A (zh) * 1994-01-06 1994-11-09 贾玉海 降糖糊
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
JPH08325156A (ja) * 1995-06-01 1996-12-10 Ichimaru Pharcos Co Ltd ステビオール配糖体含有皮膚外用剤及び飲食品
JPH0952825A (ja) * 1995-06-09 1997-02-25 Taisho Pharmaceut Co Ltd 解熱鎮痛剤
CN1148476A (zh) * 1995-10-20 1997-04-30 王国安 一种降糖保健食品添加剂及其配制方法
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
CN1065753C (zh) * 1996-12-04 2001-05-16 上海绿泰宝营养保健品有限公司 降糖冲剂及其制备方法
CN1062722C (zh) * 1997-04-04 2001-03-07 青岛海洋大学 双纤维降糖粉及其制造方法
ATE201139T1 (de) * 1997-06-13 2001-06-15 Novo Nordisk As Neue dosierung für diabetes type 2
US5980902A (en) * 1998-03-26 1999-11-09 Pharma Terra, Inc. Compositions for treating and preventing diabetes, impaired glucose tolerance and related symptoms, and methods for preparing and using such compositions
CN1184895C (zh) * 1998-07-16 2005-01-19 阿龙·塔博尔 大豆组合物及其促进健康的应用
US20030113390A1 (en) * 1998-11-25 2003-06-19 Hoie Lars Henrik Composition comprising soy protein, dietary fibers and a phytoestrogen compound and use thereof in the prevention and/or treatment of various diseases
WO2001056959A1 (en) 2000-02-01 2001-08-09 Stevia Aps A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
EP1361870A2 (en) 2001-02-01 2003-11-19 Nutri Pharma ASA A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
US20090232913A1 (en) 2005-05-02 2009-09-17 Momir Mikov Composition for the Control of Cholesterol Levels
ATE445408T1 (de) * 2005-10-20 2009-10-15 Ghc Res Dev Corp Verwendung von prolactin in der prophylaktischen krebstherapie
US20100093861A1 (en) * 2006-09-15 2010-04-15 Stevia Aps Treatment of insulin resistance or diseases associated with insulin resistance

Also Published As

Publication number Publication date
JP2003521528A (ja) 2003-07-15
EP2330092A3 (en) 2012-07-25
CA2398445A1 (en) 2001-08-09
AU3002801A (en) 2001-08-14
WO2001056959A1 (en) 2001-08-09
AU784422B2 (en) 2006-03-30
US20080318866A1 (en) 2008-12-25
US20080051341A1 (en) 2008-02-28
EP1255718A1 (en) 2002-11-13
CA2762121A1 (en) 2001-08-09
US9636314B2 (en) 2017-05-02
CN1416411A (zh) 2003-05-07
JP2012153721A (ja) 2012-08-16
CN100475757C (zh) 2009-04-08
EP2330092A2 (en) 2011-06-08
US20140094408A1 (en) 2014-04-03
US20030060428A1 (en) 2003-03-27
WO2001056959B1 (en) 2002-02-07
CA2398445C (en) 2012-04-03
US20050038126A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
BR0108043A (pt) Substância para uso em complementação de dieta ou para preparação de um medicamento para o tratamento de diabetes melito não-dependente de insulina, hipertensão e/ou sìndrome metabólica
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
Pieber et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)
BG105531A (en) Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
GEP20053538B (en) Pharmaceutical Composition Comprising A Combination of Metformin and Glyburide
EA200900626A1 (ru) Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
BRPI0518460A2 (pt) mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia'
AR012998A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente.
NO20053537L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
BRPI0418029B8 (pt) formulação farmacêutica líquida, estável, adequada para administração parentérica que compreende um anticorpo agonista de cd40
ATE227986T1 (de) Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
BR9906813A (pt) Método para administração de insulina aspb28- humana
BRPI0406499A (pt) Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2
BRPI0410260A (pt) composição conjugada para medicamento
DE60219963D1 (de) Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
ATE350024T1 (de) Flüssige zubereitung enthaltend tobramycin
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
BR0107881A (pt) Uso de fsh tratamento de infertilidade
AU2001289762A1 (en) Pharmaceutical extemporary compositions
BR0111464A (pt) Composição farmacêutica na forma de dosagem unitária, e, método de tratamento de um paciente com nefropatia diabética
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
Huff Protease inhibitor side effects take people by surprise
Thaddanee et al. SGLT-2 inhibitors: the glucosuric antidiabetics
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
Teekachunhatean et al. Effects of vitamin D plus calcium supplements on pharmacokinetics of isoflavones in thai postmenopausal women

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: STEVIA APS (DK)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060078693/RJ DE 31/05/2006.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2395 DE 29-11-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.